Michael Mason
2020
In 2020, Michael Mason earned a total compensation of $2.3M as Senior Vice President, Chief Financial Officer and Treasurer at Karyopharm Therapeutics, a 137% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $156,123 |
|---|---|
| Option Awards | $1,096,226 |
| Salary | $415,624 |
| Stock Awards | $586,963 |
| Other | $11,880 |
| Total | $2,266,816 |
Mason received $1.1M in option awards, accounting for 48% of the total pay in 2020.
Mason also received $156.1K in non-equity incentive plan, $415.6K in salary, $587K in stock awards and $11.9K in other compensation.
Rankings
In 2020, Michael Mason's compensation ranked 4,967th out of 13,090 executives tracked by ExecPay. In other words, Mason earned more than 62.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,967 out of 13,090 | 62nd |
Division Manufacturing | 2,023 out of 5,621 | 64th |
Major group Chemicals And Allied Products | 802 out of 2,254 | 64th |
Industry group Drugs | 692 out of 1,954 | 65th |
Industry Pharmaceutical Preparations | 520 out of 1,459 | 64th |
Source: SEC filing on April 7, 2021.
Mason's colleagues
We found two more compensation records of executives who worked with Michael Mason at Karyopharm Therapeutics in 2020.